M Asghari Jafarabadi , L Karimi, F Rahimi Bashar , A Vahedian Azimi ,
Volume 15, Issue 4 (Vol.15, No.4 2020)
Abstract
Background and Objectives: Progressive muscle relaxation (PMR) training as part of an educational program for patients involved in pathologic and physiological events (PPE) can have important physiological and psychological benefits for the patients, and can affect various dimensions of their lives including the quality of life. This systematic review and meta-analysis was conducted to determine the effect of PMR on the quality of life of patients involved in PPE.
Methods: Through searching the words “PMR” and “quality of life (QOL)” in Persian databases including SID, MagIran, IranMedex, and IranDoc and international databases including Google Scholar, Scopus, PubMed, Web of Science, ProQuest, and ScienceDirect, all studies published on the effect of PMR on the QOL were extracted. The methodological quality of the papers was examined using Cochrane risk of bias. Data analysis was carried out using a random-effects model and heterogeneity was assessed by I2. The data were analyzed using the STATA software version 14.0.
Results: Of 495 studies, only 10 explored the effect of PMR on the QOL of patients. The pooled mean of the QOL and all dimensions were statistically significant, including physical functioning (0.339), physical role limitation (0.378), bodily pain (0.341), general health (0.598), social functioning (0.873), mental health (0.736), emotional role limitation (0.791), vitality (0.706), total physical dimensions (0.652), total mental dimensions (1.316), and total QOF score (0.480). Only one study had a low risk of bias.
Conclusion: Implementation of PMR has a significant effect on the quality of life of patients involved in PPE. PMR is recommended to improve the QOL of the patients.
Aliasghar Fakhri-Demeshghieh, Hesameddin Akbarein, Rouzbeh Bashar, Mohammad Reza Shirzadi, Zahra Boluki, Narges Ghasemzadeh,
Volume 21, Issue 1 (Vol.21, No.1, Spring 2025)
Abstract
Background and Objectives: Rabies is a public health threat worldwide. This study aimed to determine the amount and trend of the costs of anti-rabies serum and rabies vaccine in Iran between 2015 and 2022.
Methods: Using national data from March 2015 to March 2022, the cost of anti-rabies serum, human rabies vaccine, and the total cost of both were determined. The annual trend of the serum, vaccine, and total cost was determined using Joinpoint regression with a maximum of one.
Results: The highest rabies serum and vaccine costs were observed in 2021 and 2020 (58.3 and 6.874 US million dollars), respectively. Average Annual Percent Change was statistically significant (p<0.001) and indicated an increasing trend in the costs of anti-rabies serum. The trend in vaccine costs between 2015 and 2020 was increasing, and the annual percent change between 2015 and 2020 (p˂0.001) and 2021 (p˂0.001) were statistically significant. The average annual percentage change was statistically significant for the total costs of anti-rabies serum and rabies vaccine (p˂0.001) and indicated an increasing trend in Iran.
Conclusion: The lowest rabies vaccine costs were observed in 2021, which might be due to the COVID-19 pandemic. To reduce rabies losses, the domestic production of anti-rabies serum, implementing rabies control measures in unowned dogs, and increasing public awareness about animal bites, particularly dog bites, are recommended.
